Safety and Efficacy of Multiple Escalating Doses of RC28-E for Neovascular Age-Related Macular Degeneration: A Phase 1b Trial.

Yingyi LuXiaobing YuYouxin ChenChan WuQin JiangShaoping HaDan ZhuYanlong BiXiaoling LiuHan ZhangZhuo LiWenxiang WangLin LiHe ChenYifan ZhangHong DaiJianmin Fang

Published in: Ophthalmology and therapy (2024)

RC28-E was well tolerated and exhibited an overall favorable safety profile with evidence of improvements in BCVA and anatomical parameters.

Keyphrases

age related macular degeneration
phase iii
study protocol
clinical trial
phase ii
randomized controlled trial
double blind